PKM and metabolic dysfunction-associated steatohepatitis: Thus far, therapeutic targeting of PKM2 has been shown to ameliorate a broad spectrum of chronic liver diseases, ranging from alcoholic liver disease to nonalcoholic steatohepatitis (NASH) (Qu et al., 2023).